ReviewFrontiers in oncology2022
The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Chronic Infections as Catalysts for Melanoma Aggressiveness: Insights into Tumour Microenvironment Modulation.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Monopolar Radiofrequency for Facial Hyperpigmentation Treatment: An Integrated Retrospective Clinical Trial and Ex Vivo Study.International journal of molecular sciences · 2026Trial
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine.Journal of advanced research · 2026Review
- Exploring the immune landscape of melanoma of the lower female genital tract.Virchows Archiv : an international journal of pathology · 2026Article
- QUILPEN Provides Independent and Label-Free Single-Cell Quantification of Pigmentation Dynamics and Organelle Content.Pigment cell & melanoma research · 2026Article
- Pmel17 Deficiency Affects Melanogenesis and Promotes Tumor Vascularization.International journal of molecular sciences · 2026Article
- Global Burden and Drivers of Cutaneous Malignant Melanoma Among Women Aged 55 and Older.International journal of women's health · 2026Article
- Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study.Nature communications · 2025Article
- Implications of Altered Endosomal-Lysosomal Biogenesis in Melanoma Pathogenesis.International journal of molecular sciences · 2025Review
- A novel liphagal analog, IIIM-321, induces apoptosis in melanoma cells via autophagy modulation and PI3K/MAPK pathway inhibition.Cytotechnology · 2025Article
- Photoreactive Properties of Melanin Obtained from Human Induced Pluripotent Stem Cell-Derived Melanocytes.International journal of molecular sciences · 2025Article
- Non-Melanoma Skin Cancer: Dermatoscopic Diagnostic Clues in Mexican Individuals Based on Fitzpatrick Skin Phototypes.Journal of clinical medicine · 2025Article
- SPRY1 regulates macrophage M1 polarization in skin aging and melanoma prognosis.Translational oncology · 2025Article
- Salidroside inhibits melanin synthesis and melanoma growth via mTOR and PI3K/Akt pathways.Frontiers in oncology · 2025Article
- Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.Frontiers in pharmacology · 2025Article
- Vaginal Mucosal Melanoma Cell Activation in Response to Photon or Carbon Ion Irradiation.International journal of particle therapy · 2024Article
- Association of Cytotoxic T-Lymphocyte Antigen-4 (International journal of molecular sciences · 2024Article
- The Invisible Fraction within Melanin Capable of Absorbing UV Light and with Fluorescent Properties: Is It Lacking Consideration?International journal of molecular sciences · 2024Article
- Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future Perspectives.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancers are among the most common cancers worldwide and are increasingly prevalent. Cutaneous melanoma (CM) is characterized by the malignant transformation of melanocytes in the epidermis. Although CM shows lower incidence than other skin cancers, it is the most aggressive and responsible for the vast majority of skin cancer-related deaths. Indeed, 75% of patients present with invasive or metastatic tumors, even after surgical excision. In CM, the photoprotective pigment melanin, which is produced by melanocytes, plays a central role in the pathology of the disease. Melanin absorbs ultraviolet radiation and scavenges reactive oxygen/nitrogen species (ROS/RNS) resulting from the radiation exposure. However, the scavenged ROS/RNS modify melanin and lead to the induction of signature DNA damage in CM cells, namely cyclobutane pyrimidine dimers, which are known to promote CM immortalization and carcinogenesis. Despite triggering the malignant transformation of melanocytes and promoting initial tumor growth, the presence of melanin inside CM cells is described to negatively regulate their invasiveness by increasing cell stiffness and reducing elasticity. Emerging evidence also indicates that melanin secreted from CM cells is required for the immunomodulation of tumor microenvironment. Indeed, melanin transforms dermal fibroblasts in cancer-associated fibroblasts, suppresses the immune system and promotes tumor angiogenesis, thus sustaining CM progression and metastasis. Here, we review the current knowledge on the role of melanin secretion in CM aggressiveness and the molecular machinery involved, as well as the impact in tumor microenvironment and immune responses. A better understanding of this role and the molecular players involved could enable the modulation of melanin secretion to become a therapeutic strategy to impair CM invasion and metastasis and, hence, reduce the burden of CM-associated deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.